MA47167A - Composés pyrazolopyrimidine et leurs procédés d'utilisation - Google Patents
Composés pyrazolopyrimidine et leurs procédés d'utilisationInfo
- Publication number
- MA47167A MA47167A MA047167A MA47167A MA47167A MA 47167 A MA47167 A MA 47167A MA 047167 A MA047167 A MA 047167A MA 47167 A MA47167 A MA 47167A MA 47167 A MA47167 A MA 47167A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- pyrazolopyrimidine compounds
- pyrazolopyrimidine
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016112932 | 2016-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47167A true MA47167A (fr) | 2019-11-06 |
Family
ID=61094385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047167A MA47167A (fr) | 2016-12-29 | 2017-12-22 | Composés pyrazolopyrimidine et leurs procédés d'utilisation |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11155557B2 (fr) |
| EP (1) | EP3562809B1 (fr) |
| JP (1) | JP6900491B2 (fr) |
| KR (1) | KR20190100337A (fr) |
| CN (1) | CN110114343B (fr) |
| AU (1) | AU2017385543A1 (fr) |
| BR (1) | BR112019013287A2 (fr) |
| CA (1) | CA3046435A1 (fr) |
| CL (1) | CL2019001694A1 (fr) |
| CO (1) | CO2019006220A2 (fr) |
| CR (1) | CR20190310A (fr) |
| IL (1) | IL267671A (fr) |
| MA (1) | MA47167A (fr) |
| MX (1) | MX2019007339A (fr) |
| PE (1) | PE20191236A1 (fr) |
| PH (1) | PH12019501022A1 (fr) |
| RU (1) | RU2019123319A (fr) |
| WO (1) | WO2018122212A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019013287A2 (pt) | 2016-12-29 | 2019-12-24 | Hoffmann La Roche | compostos de pirazolopirimidina e métodos de uso dos mesmos |
| MX2019013308A (es) | 2017-05-22 | 2020-02-12 | Hoffmann La Roche | Composiciones y compuestos terapeuticos, y metodos para su uso. |
| EP3740488A1 (fr) * | 2018-01-15 | 2020-11-25 | F. Hoffmann-La Roche AG | Composés pyrazolopyrimidine utilisés en tant qu'inhibiteurs de jak |
| JP2022537354A (ja) * | 2019-06-18 | 2022-08-25 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｊａｋキナーゼのピラゾロピリミジンアリールエーテル阻害剤及びその使用 |
| EP3986900A1 (fr) * | 2019-06-18 | 2022-04-27 | F. Hoffmann-La Roche AG | Inhibiteurs de pyrazolopyrimidine à substitution tétrazole de kinases jak et leurs utilisations |
| CA3140024A1 (fr) | 2019-06-18 | 2020-12-24 | Mark Edward Zak | Inhibiteurs de sulfone pyrazolopyrimidine de jak kinases et leurs utilisations |
| WO2022175829A1 (fr) * | 2021-02-17 | 2022-08-25 | Cellix Bio Private Limited | Formulations et compositions topiques |
| WO2024052513A1 (fr) * | 2022-09-09 | 2024-03-14 | Chiesi Farmaceutici S.P.A. | Dérivés hétérocycliques comme inhibiteurs de janus kinase |
| WO2024052512A1 (fr) * | 2022-09-09 | 2024-03-14 | Chiesi Farmaceutici S.P.A. | Dérivés hétérocycliques comme inhibiteurs de janus kinase |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| AU6311996A (en) | 1995-07-06 | 1997-02-05 | Zeneca Limited | Peptide inhibitors of fibronectine |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1241176A1 (fr) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Dérivés de purine pour le traitement de l'ischémie |
| WO2003053930A1 (fr) | 2001-12-20 | 2003-07-03 | Bayer Healthcare Ag | Derives de 1,4-dihydro-1,4-diphenylpyridine |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| EP2251341A1 (fr) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Hétérocycles inhibiteurs de Janus kinase-3 |
| MX2010014005A (es) | 2008-06-20 | 2011-02-15 | Genentech Inc | Compuestos de triazolopiridina inhibidores de jak y los metodos. |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| MX2016015062A (es) * | 2014-05-23 | 2017-02-27 | Hoffmann La Roche | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina los cuales son inhibidores de janus cinasas (jak). |
| TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| JP6936236B2 (ja) | 2016-02-18 | 2021-09-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 治療化合物、組成物及びその方法の使用 |
| SG11201811697SA (en) | 2016-06-29 | 2019-01-30 | Hanmi Pharmaceutical Co Ltd | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
| BR112019013287A2 (pt) | 2016-12-29 | 2019-12-24 | Hoffmann La Roche | compostos de pirazolopirimidina e métodos de uso dos mesmos |
-
2017
- 2017-12-22 BR BR112019013287A patent/BR112019013287A2/pt not_active Application Discontinuation
- 2017-12-22 KR KR1020197022055A patent/KR20190100337A/ko not_active Application Discontinuation
- 2017-12-22 MA MA047167A patent/MA47167A/fr unknown
- 2017-12-22 WO PCT/EP2017/084569 patent/WO2018122212A1/fr unknown
- 2017-12-22 CR CR20190310A patent/CR20190310A/es unknown
- 2017-12-22 AU AU2017385543A patent/AU2017385543A1/en not_active Abandoned
- 2017-12-22 PE PE2019001227A patent/PE20191236A1/es unknown
- 2017-12-22 CA CA3046435A patent/CA3046435A1/fr not_active Abandoned
- 2017-12-22 MX MX2019007339A patent/MX2019007339A/es unknown
- 2017-12-22 CN CN201780081495.7A patent/CN110114343B/zh active Active
- 2017-12-22 RU RU2019123319A patent/RU2019123319A/ru not_active Application Discontinuation
- 2017-12-22 EP EP17836033.5A patent/EP3562809B1/fr active Active
- 2017-12-22 JP JP2019535901A patent/JP6900491B2/ja active Active
-
2019
- 2019-05-08 PH PH12019501022A patent/PH12019501022A1/en unknown
- 2019-06-14 CO CONC2019/0006220A patent/CO2019006220A2/es unknown
- 2019-06-19 CL CL2019001694A patent/CL2019001694A1/es unknown
- 2019-06-25 US US16/452,058 patent/US11155557B2/en active Active
- 2019-06-26 IL IL267671A patent/IL267671A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190100337A (ko) | 2019-08-28 |
| JP2020503339A (ja) | 2020-01-30 |
| EP3562809A1 (fr) | 2019-11-06 |
| PE20191236A1 (es) | 2019-09-11 |
| IL267671A (en) | 2019-08-29 |
| RU2019123319A3 (fr) | 2021-02-01 |
| CA3046435A1 (fr) | 2018-07-05 |
| PH12019501022A1 (en) | 2019-12-16 |
| BR112019013287A2 (pt) | 2019-12-24 |
| JP6900491B2 (ja) | 2021-07-07 |
| EP3562809B1 (fr) | 2021-06-09 |
| CN110114343B (zh) | 2022-09-06 |
| CN110114343A (zh) | 2019-08-09 |
| US20190345165A1 (en) | 2019-11-14 |
| MX2019007339A (es) | 2019-09-06 |
| RU2019123319A (ru) | 2021-02-01 |
| WO2018122212A1 (fr) | 2018-07-05 |
| CR20190310A (es) | 2019-08-21 |
| AU2017385543A1 (en) | 2019-05-23 |
| CL2019001694A1 (es) | 2019-11-22 |
| CO2019006220A2 (es) | 2019-06-28 |
| US11155557B2 (en) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
| MA47167A (fr) | Composés pyrazolopyrimidine et leurs procédés d'utilisation | |
| MA43827A (fr) | Composés di-nucléotides cycliques et leurs procédés d'utilisation | |
| MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA43284A (fr) | Composés et leurs méthodes d'utilisation | |
| MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA46565A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
| MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| MA54252A (fr) | Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation | |
| MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| MA42302A (fr) | Lactames bicycliques et leurs méthodes d'utilisation | |
| MA44740A (fr) | Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation | |
| MA42409A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
| MA41999A (fr) | Compositions d'acide obéticholique et procédés d'utilisation | |
| MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
| MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
| MA43389A (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
| MA54851A (fr) | Oxystérols et leurs procédés d'utilisation | |
| MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
| MA46546A (fr) | Composés thérapeutiques et leurs procédés d'utilisation | |
| MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |